

SN 10/613,914

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jerome P. Horwitz et al.

Examiner: Sabiha Naim Qazi

Serial No.: 10/613,914

Group Art Unit: 1616

Filed: July 03, 2003

Docket: 1319.007US1

Title: THERAPEUTIC AMIDES

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609; Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

INFORMATION DISCLOSURE STATEMENT

Serial No : 10/613,914

Filing Date: July 03, 2003

Title: THERAPEUTIC AMIDES

Page 2

Dkt: 1319.007US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

Respectfully submitted,

JEROME P. HORWITZ ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6968

Date

Aug 2, 2005

By

William F. Prout

William F. Prout

Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 2 day of August, 2005.

Name

Kate Gannon

Signature


[Signature]

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/613,914
Filing Date	July 3, 2003
First Named Inventor	Horwitz, Jerome
Group Art Unit	1616
Examiner Name	Sabiha Naim Qazi

Sheet 1 of 1

Attorney Docket No: 1319.007US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-4,559,157	12/17/1985	Smith, James A., et al.	04/21/1983
	US-4,608,392	08/26/1986	Jacquet, B., et al.	08/28/1984
	US-4,710,507	12/01/1987	Campbell, Simon F., et al.	12/18/1984
	US-4,820,508	04/11/1989	Wortzman, M. S.	06/23/1987
	US-4,938,949	07/03/1990	Borch, R. F., et al.	09/12/1988
	US-4,992,478	02/12/1991	Geria, Navin M.	04/04/1988
	US-5,364,831	11/15/1994	Yasukazu, et al.	08/06/1980
	US-6,197,728	03/06/2001	Yasukazu, et al.	08/30/1994

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		"International Search Report , Application No. PCT/US 03/21062, Date mailed November 3, 2003", 8 Pages	
		CORBETT, T. H., "Preclinical Antitumor Efficacy of Analogs of XK469: Sodium-(2-[4-(7-Chloro-2-Quinoxalinyloxy)Phenoxy]Propionate", <u>Investigational New Drugs</u> , 16, (1998),129-139	
		HAZELDINE, STUART T., "J. Med. Chem., 2002, 45", <u>II. Synthesis and Biological Evaluation of Some Bioisosteres and Congeners of the Antitumor Agent, 2-[4-[(7-Chloro-2-quinoxalinyloxy)phenoxy]propionic Acid (XK469)</u> , (2002),3130-3137	
		TIETZE, L. F., et al., "Improved Synthesis of (E)-3-Alkoxy- and (E)-3-Phenoxyacryloyl Chlorides", <u>SYNTHESIS</u> , (November 1993),1079-1080	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached